{
	"File": {
		"__typename": "FileMatch",
		"repository": {
			"name": "github.com/Chinlinlee/Burni"
		},
		"file": {
			"name": "swagger.json",
			"size": 0,
			"path": "docs/apidoc/redoc/MedicinalProductInteraction/swagger.json",
			"byteSize": 61851,
			"content": "{\"openapi\":\"3.0.0\",\"servers\":[{\"url\":\"https://dev.burni.xn--7-c56d.com/\"}],\"info\":{\"title\":\"Burni API documentation\",\"version\":\"v2.1.0\",\"description\":\"Documentation for the REST API\"},\"paths\":{\"/fhir/MedicinalProductInteraction\":{\"post\":{\"operationId\":\"createMedicinalProductInteraction\",\"tags\":[\"MedicinalProductInteraction\"],\"summary\":\"create MedicinalProductInteraction resource.\",\"parameters\":[],\"requestBody\":{\"content\":{\"application/fhir+json\":{\"schema\":{\"$ref\":\"#/components/schemas/createMedicinalProductInteraction\"},\"examples\":{\"json-example\":{\"value\":{\"resourceType\":\"MedicinalProductInteraction\",\"id\":\"example\",\"text\":{\"status\":\"generated\",\"div\":\"\u003cdiv xmlns=\\\"http://www.w3.org/1999/xhtml\\\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative with Details\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: example\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: ketoconazole \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: itraconazole \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: StrongInhibitorofCYP3A4 \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eeffect\u003c/b\u003e: Increasedplasmaconcentrations \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003emanagement\u003c/b\u003e: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp \u003cspan\u003e(Details )\u003c/span\u003e\u003c/p\u003e\u003c/div\u003e\"},\"description\":\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\",\"interactant\":[{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"ketoconazole\"}]}},{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"itraconazole\"}]}}],\"type\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionsType\",\"code\":\"StrongInhibitorofCYP3A4\"}]},\"effect\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionseffect\",\"code\":\"Increasedplasmaconcentrations\"}]},\"management\":{\"text\":\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\"},\"meta\":{\"tag\":[{\"system\":\"http://terminology.hl7.org/CodeSystem/v3-ActReason\",\"code\":\"HTEST\",\"display\":\"test health data\"}]}}}}},\"application/fhir+xml\":{\"schema\":{\"$ref\":\"#/components/schemas/createMedicinalProductInteraction\",\"xml\":{\"name\":\"MedicinalProductInteraction\"}},\"examples\":{\"xml-example\":{\"value\":\"\\n\u003c?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?\u003e\u003cMedicinalProductInteraction xmlns=\\\"http://hl7.org/fhir\\\"\u003e\u003cid value=\\\"example\\\"/\u003e\u003cmeta\u003e\u003ctag\u003e\u003csystem value=\\\"http://terminology.hl7.org/CodeSystem/v3-ActReason\\\"/\u003e\u003ccode value=\\\"HTEST\\\"/\u003e\u003cdisplay value=\\\"test health data\\\"/\u003e\u003c/tag\u003e\u003c/meta\u003e\u003ctext\u003e\u003cstatus value=\\\"generated\\\"/\u003e\u003cdiv xmlns=\\\"http://www.w3.org/1999/xhtml\\\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative with Details\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: example\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: ketoconazole \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: itraconazole \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: StrongInhibitorofCYP3A4 \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eeffect\u003c/b\u003e: Increasedplasmaconcentrations \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003emanagement\u003c/b\u003e: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp \u003cspan\u003e(Details )\u003c/span\u003e\u003c/p\u003e\u003c/div\u003e\u003c/text\u003e\u003cdescription value=\\\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\\\"/\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"ketoconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"itraconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003ctype\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionsType\\\"/\u003e\u003ccode value=\\\"StrongInhibitorofCYP3A4\\\"/\u003e\u003c/coding\u003e\u003c/type\u003e\u003ceffect\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionseffect\\\"/\u003e\u003ccode value=\\\"Increasedplasmaconcentrations\\\"/\u003e\u003c/coding\u003e\u003c/effect\u003e\u003cmanagement\u003e\u003ctext value=\\\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\\\"/\u003e\u003c/management\u003e\u003c/MedicinalProductInteraction\u003e\"}}}}},\"description\":\"create MedicinalProductInteraction resource.\",\"responses\":{\"200\":{\"description\":\"successful operation\",\"content\":{\"application/fhir+json\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"}},\"examples\":{\"json-example\":{\"value\":{\"resourceType\":\"MedicinalProductInteraction\",\"id\":\"34868be2-3b67-4938-8c82-de12c8506b93\",\"description\":\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\",\"interactant\":[{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"ketoconazole\"}]}},{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"itraconazole\"}]}}],\"type\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionsType\",\"code\":\"StrongInhibitorofCYP3A4\"}]},\"effect\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionseffect\",\"code\":\"Increasedplasmaconcentrations\"}]},\"management\":{\"text\":\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\"},\"meta\":{\"tag\":[{\"system\":\"http://terminology.hl7.org/CodeSystem/v3-ActReason\",\"code\":\"HTEST\",\"display\":\"test health data\"}],\"versionId\":\"1\",\"lastUpdated\":\"2022-02-13T22:30:17.988+08:00\"}}}}},\"application/fhir+xml\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"},\"xml\":{\"name\":\"MedicinalProductInteraction\"}},\"examples\":{\"xml-example\":{\"value\":\"\u003c?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?\u003e\u003cMedicinalProductInteraction xmlns=\\\"http://hl7.org/fhir\\\"\u003e\u003cid value=\\\"936a22b3-5ea8-4f97-9105-300c41e8776b\\\"/\u003e\u003cmeta\u003e\u003cversionId value=\\\"1\\\"/\u003e\u003clastUpdated value=\\\"2022-02-17T17:34:54.876+08:00\\\"/\u003e\u003ctag\u003e\u003csystem value=\\\"http://terminology.hl7.org/CodeSystem/v3-ActReason\\\"/\u003e\u003ccode value=\\\"HTEST\\\"/\u003e\u003cdisplay value=\\\"test health data\\\"/\u003e\u003c/tag\u003e\u003c/meta\u003e\u003cdescription value=\\\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\\\"/\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"ketoconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"itraconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003ctype\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionsType\\\"/\u003e\u003ccode value=\\\"StrongInhibitorofCYP3A4\\\"/\u003e\u003c/coding\u003e\u003c/type\u003e\u003ceffect\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionseffect\\\"/\u003e\u003ccode value=\\\"Increasedplasmaconcentrations\\\"/\u003e\u003c/coding\u003e\u003c/effect\u003e\u003cmanagement\u003e\u003ctext value=\\\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\\\"/\u003e\u003c/management\u003e\u003c/MedicinalProductInteraction\u003e\"}}}}},\"400\":{\"description\":\"error\",\"content\":{\"application/fhir+json\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"}},\"examples\":{\"Bad-Request-Response\":{\"value\":{\"resourceType\":\"OperationOutcome\",\"issue\":[{\"severity\":\"error\",\"code\":\"exception\",\"diagnostics\":\"validation error, path `resourceType` is required\"}]}}}},\"application/fhir+xml\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"},\"xml\":{\"name\":\"OperationOutcome\"}},\"examples\":{\"Bad-Request-Response\":{\"value\":\"\\n\u003cOperationOutcome xmlns='http://hl7.org/fhir'\u003e\\n\u003cissue\u003e\\n    \u003cseverity value='error'/\u003e\\n    \u003ccode value='exception'/\u003e\\n    \u003cdiagnostics value='validation error, path `resourceType` is required'/\u003e\\n\u003c/issue\u003e\\n\u003c/OperationOutcome\u003e\"}}}}}},\"x-codeSamples\":[{\"lang\":\"Shell\",\"source\":\"#example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\\ncurl --location --request POST 'http://burni.example.com/fhir/MedicinalProductInteraction \\\\' \\n--header 'Content-Type: application/fhir+json' \\\\\\n--data-raw '{\\\"resourceType\\\":\\\"MedicinalProductInteraction\\\",\\\"id\\\":\\\"34868be2-3b67-4938-8c82-de12c8506b93\\\",\\\"description\\\":\\\"Inhibitors of CYP3A4 and P-gp\\\\\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\\\\\nequixaban Cmax.\\\\\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\\\\\nsection 4.4).\\\\\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\\\",\\\"interactant\\\":[{\\\"itemCodeableConcept\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactant\\\",\\\"code\\\":\\\"ketoconazole\\\"}]}},{\\\"itemCodeableConcept\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactant\\\",\\\"code\\\":\\\"itraconazole\\\"}]}}],\\\"type\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactionsType\\\",\\\"code\\\":\\\"StrongInhibitorofCYP3A4\\\"}]},\\\"effect\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactionseffect\\\",\\\"code\\\":\\\"Increasedplasmaconcentrations\\\"}]},\\\"management\\\":{\\\"text\\\":\\\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\\\"},\\\"meta\\\":{\\\"tag\\\":[{\\\"system\\\":\\\"http://terminology.hl7.org/CodeSystem/v3-ActReason\\\",\\\"code\\\":\\\"HTEST\\\",\\\"display\\\":\\\"test health data\\\"}],\\\"versionId\\\":\\\"1\\\",\\\"lastUpdated\\\":\\\"2022-02-13T22:30:17.988+08:00\\\"}}'\",\"label\":\"cURL\"},{\"lang\":\"JavaScript\",\"source\":\" //example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\\nconst axios = require('axios');\\nconst data = {\\\"resourceType\\\":\\\"MedicinalProductInteraction\\\",\\\"id\\\":\\\"34868be2-3b67-4938-8c82-de12c8506b93\\\",\\\"description\\\":\\\"Inhibitors of CYP3A4 and P-gp\\\\\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\\\\\nequixaban Cmax.\\\\\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\\\\\nsection 4.4).\\\\\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\\\",\\\"interactant\\\":[{\\\"itemCodeableConcept\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactant\\\",\\\"code\\\":\\\"ketoconazole\\\"}]}},{\\\"itemCodeableConcept\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactant\\\",\\\"code\\\":\\\"itraconazole\\\"}]}}],\\\"type\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactionsType\\\",\\\"code\\\":\\\"StrongInhibitorofCYP3A4\\\"}]},\\\"effect\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactionseffect\\\",\\\"code\\\":\\\"Increasedplasmaconcentrations\\\"}]},\\\"management\\\":{\\\"text\\\":\\\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\\\"},\\\"meta\\\":{\\\"tag\\\":[{\\\"system\\\":\\\"http://terminology.hl7.org/CodeSystem/v3-ActReason\\\",\\\"code\\\":\\\"HTEST\\\",\\\"display\\\":\\\"test health data\\\"}],\\\"versionId\\\":\\\"1\\\",\\\"lastUpdated\\\":\\\"2022-02-13T22:30:17.988+08:00\\\"}}\\nconst config = {\\n    method: 'post',\\n    url: 'http://burni.example.com/fhir/MedicinalProductInteraction',\\n    headers: { \\n        'Content-Type': 'application/fhir+json'\\n    },\\n    data: data\\n};\\n\\naxios(config)\\n.then(function (response) {\\n    console.log(JSON.stringify(response.data));\\n})\\n.catch(function (error) {\\n    console.log(error);\\n});\",\"label\":\"javascript Axios\"}]}},\"/fhir/MedicinalProductInteraction/{id}\":{\"delete\":{\"operationId\":\"deleteMedicinalProductInteraction\",\"tags\":[\"MedicinalProductInteraction\"],\"summary\":\"delete MedicinalProductInteraction resource by id.\",\"parameters\":[{\"name\":\"id\",\"in\":\"path\",\"required\":true,\"schema\":{\"type\":\"string\"},\"description\":\"Resource ID in server\"}],\"responses\":{\"200\":{\"description\":\"successful operation\",\"content\":{\"application/fhir+json\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"}},\"examples\":{\"Success-Response\":{\"value\":{\"resourceType\":\"OperationOutcome\",\"issue\":[{\"severity\":\"information\",\"code\":\"informational\",\"diagnostics\":\"delete MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93 successfully\"}]}}}},\"application/fhir+xml\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"},\"xml\":{\"name\":\"OperationOutcome\"}},\"examples\":{\"Success-Response-XML\":{\"value\":\"\u003cOperationOutcome xmlns='http://hl7.org/fhir'\u003e\\n    \u003cissue\u003e\\n    \u003cseverity value='information'/\u003e\\n    \u003ccode value='informational'/\u003e\\n    \u003cdiagnostics value='delete MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93 successfully'/\u003e\\n    \u003c/issue\u003e\\n\u003c/OperationOutcome\u003e\"}}}}},\"404\":{\"description\":\"error\",\"content\":{\"application/fhir+json\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"}},\"examples\":{\"Not-Found-Response\":{\"value\":{\"resourceType\":\"OperationOutcome\",\"issue\":[{\"severity\":\"error\",\"code\":\"exception\",\"diagnostics\":\"The id-\u003e34868be2-3b67-4938-8c82-de12c8506b93 not found in MedicinalProductInteraction resource\"}]}}}},\"application/fhir+xml\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"},\"xml\":{\"name\":\"OperationOutcome\"}},\"examples\":{\"Not-Found-Response-XML\":{\"value\":\"\u003cOperationOutcome xmlns='http://hl7.org/fhir'\u003e\\n    \u003cissue\u003e\\n    \u003cseverity value='error'/\u003e\\n    \u003ccode value='not-found'/\u003e\\n    \u003cdiagnostics value='The id-\u0026gt;34868be2-3b67-4938-8c82-de12c8506b93  not found in MedicinalProductInteraction resource'/\u003e\\n    \u003c/issue\u003e\\n\u003c/OperationOutcome\u003e\"}}}}}},\"x-codeSamples\":[{\"lang\":\"Shell\",\"source\":\"#example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\\ncurl --location --request DELETE 'http://burni.example.com/fhir/MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93'\",\"label\":\"cURL\"},{\"lang\":\"JavaScript\",\"source\":\" //example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\\nconst axios = require('axios');\\nconst config = {\\n    method: 'delete',\\n    url: 'http://burni.example.com/fhir/MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93'\\n};\\n\\naxios(config)\\n.then(function (response) {\\n    console.log(JSON.stringify(response.data));\\n})\\n.catch(function (error) {\\n    console.log(error);\\n});\",\"label\":\"javascript Axios\"}]},\"get\":{\"operationId\":\"readMedicinalProductInteraction\",\"tags\":[\"MedicinalProductInteraction\"],\"summary\":\"read MedicinalProductInteraction resource by id.\",\"parameters\":[{\"name\":\"id\",\"in\":\"path\",\"required\":true,\"schema\":{\"type\":\"string\"},\"description\":\"Resource ID in server\"}],\"responses\":{\"200\":{\"description\":\"successful operation\",\"content\":{\"application/fhir+json\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"}},\"examples\":{\"Success-Response\":{\"value\":{\"resourceType\":\"MedicinalProductInteraction\",\"id\":\"34868be2-3b67-4938-8c82-de12c8506b93\",\"description\":\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\",\"interactant\":[{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"ketoconazole\"}]}},{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"itraconazole\"}]}}],\"type\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionsType\",\"code\":\"StrongInhibitorofCYP3A4\"}]},\"effect\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionseffect\",\"code\":\"Increasedplasmaconcentrations\"}]},\"management\":{\"text\":\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\"},\"meta\":{\"tag\":[{\"system\":\"http://terminology.hl7.org/CodeSystem/v3-ActReason\",\"code\":\"HTEST\",\"display\":\"test health data\"}],\"versionId\":\"1\",\"lastUpdated\":\"2022-02-13T22:30:17.988+08:00\"}}}}},\"application/fhir+xml\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"},\"xml\":{\"name\":\"MedicinalProductInteraction\"}},\"examples\":{\"Success-Response-XML\":{\"value\":\"\u003c?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?\u003e\u003cMedicinalProductInteraction xmlns=\\\"http://hl7.org/fhir\\\"\u003e\u003cid value=\\\"936a22b3-5ea8-4f97-9105-300c41e8776b\\\"/\u003e\u003cmeta\u003e\u003cversionId value=\\\"1\\\"/\u003e\u003clastUpdated value=\\\"2022-02-17T17:34:54.876+08:00\\\"/\u003e\u003ctag\u003e\u003csystem value=\\\"http://terminology.hl7.org/CodeSystem/v3-ActReason\\\"/\u003e\u003ccode value=\\\"HTEST\\\"/\u003e\u003cdisplay value=\\\"test health data\\\"/\u003e\u003c/tag\u003e\u003c/meta\u003e\u003cdescription value=\\\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\\\"/\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"ketoconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"itraconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003ctype\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionsType\\\"/\u003e\u003ccode value=\\\"StrongInhibitorofCYP3A4\\\"/\u003e\u003c/coding\u003e\u003c/type\u003e\u003ceffect\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionseffect\\\"/\u003e\u003ccode value=\\\"Increasedplasmaconcentrations\\\"/\u003e\u003c/coding\u003e\u003c/effect\u003e\u003cmanagement\u003e\u003ctext value=\\\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\\\"/\u003e\u003c/management\u003e\u003c/MedicinalProductInteraction\u003e\"}}}}},\"404\":{\"description\":\"error\",\"content\":{\"application/fhir+json\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"}},\"examples\":{\"Not-Found-Response\":{\"value\":{\"resourceType\":\"OperationOutcome\",\"issue\":[{\"severity\":\"error\",\"code\":\"exception\",\"diagnostics\":\"not found MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93\"}]}}}},\"application/fhir+xml\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"},\"xml\":{\"name\":\"OperationOutcome\"}},\"examples\":{\"Not-Found-Response-XML\":{\"value\":\"\u003cOperationOutcome xmlns='http://hl7.org/fhir'\u003e\\n\u003cissue\u003e\\n    \u003cseverity value='error'/\u003e\\n    \u003ccode value='exception'/\u003e\\n    \u003cdiagnostics value='not found MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93'/\u003e\\n\u003c/issue\u003e\\n\u003c/OperationOutcome\u003e\"}}}}}},\"x-codeSamples\":[{\"lang\":\"Shell\",\"source\":\"#example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\\ncurl --location --request GET 'http://burni.example.com/fhir/MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93'\",\"label\":\"cURL\"},{\"lang\":\"JavaScript\",\"source\":\" //example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\\nconst axios = require('axios');\\nconst config = {\\n    method: 'get',\\n    url: 'http://burni.example.com/fhir/MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93'\\n};\\n\\naxios(config)\\n.then(function (response) {\\n    console.log(JSON.stringify(response.data));\\n})\\n.catch(function (error) {\\n    console.log(error);\\n});\",\"label\":\"javascript Axios\"}]},\"put\":{\"operationId\":\"updateMedicinalProductInteraction\",\"tags\":[\"MedicinalProductInteraction\"],\"summary\":\"update MedicinalProductInteraction resource.\",\"parameters\":[{\"name\":\"id\",\"in\":\"path\",\"required\":true,\"schema\":{\"type\":\"string\"},\"description\":\"Resource ID that you want to update\"}],\"requestBody\":{\"content\":{\"application/fhir+json\":{\"schema\":{\"$ref\":\"#/components/schemas/updateMedicinalProductInteraction\"},\"examples\":{\"json-example\":{\"value\":{\"resourceType\":\"MedicinalProductInteraction\",\"id\":\"example\",\"text\":{\"status\":\"generated\",\"div\":\"\u003cdiv xmlns=\\\"http://www.w3.org/1999/xhtml\\\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative with Details\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: example\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: ketoconazole \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: itraconazole \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: StrongInhibitorofCYP3A4 \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eeffect\u003c/b\u003e: Increasedplasmaconcentrations \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003emanagement\u003c/b\u003e: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp \u003cspan\u003e(Details )\u003c/span\u003e\u003c/p\u003e\u003c/div\u003e\"},\"description\":\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\",\"interactant\":[{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"ketoconazole\"}]}},{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"itraconazole\"}]}}],\"type\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionsType\",\"code\":\"StrongInhibitorofCYP3A4\"}]},\"effect\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionseffect\",\"code\":\"Increasedplasmaconcentrations\"}]},\"management\":{\"text\":\"Fa3DHffh0FEh4SC07X\"},\"meta\":{\"tag\":[{\"system\":\"http://terminology.hl7.org/CodeSystem/v3-ActReason\",\"code\":\"HTEST\",\"display\":\"T03Ke3vZhQ\"}]}}}}},\"application/fhir+xml\":{\"schema\":{\"$ref\":\"#/components/schemas/updateMedicinalProductInteraction\",\"xml\":{\"name\":\"MedicinalProductInteraction\"}},\"examples\":{\"xml-example\":{\"value\":\"\\n\u003c?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?\u003e\u003cMedicinalProductInteraction xmlns=\\\"http://hl7.org/fhir\\\"\u003e\u003cid value=\\\"example\\\"/\u003e\u003cmeta\u003e\u003ctag\u003e\u003csystem value=\\\"http://terminology.hl7.org/CodeSystem/v3-ActReason\\\"/\u003e\u003ccode value=\\\"HTEST\\\"/\u003e\u003cdisplay value=\\\"T03Ke3vZhQ\\\"/\u003e\u003c/tag\u003e\u003c/meta\u003e\u003ctext\u003e\u003cstatus value=\\\"generated\\\"/\u003e\u003cdiv xmlns=\\\"http://www.w3.org/1999/xhtml\\\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative with Details\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: example\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: ketoconazole \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: itraconazole \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: StrongInhibitorofCYP3A4 \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eeffect\u003c/b\u003e: Increasedplasmaconcentrations \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003emanagement\u003c/b\u003e: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp \u003cspan\u003e(Details )\u003c/span\u003e\u003c/p\u003e\u003c/div\u003e\u003c/text\u003e\u003cdescription value=\\\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\\\"/\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"ketoconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"itraconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003ctype\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionsType\\\"/\u003e\u003ccode value=\\\"StrongInhibitorofCYP3A4\\\"/\u003e\u003c/coding\u003e\u003c/type\u003e\u003ceffect\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionseffect\\\"/\u003e\u003ccode value=\\\"Increasedplasmaconcentrations\\\"/\u003e\u003c/coding\u003e\u003c/effect\u003e\u003cmanagement\u003e\u003ctext value=\\\"Fa3DHffh0FEh4SC07X\\\"/\u003e\u003c/management\u003e\u003c/MedicinalProductInteraction\u003e\"}}}}},\"description\":\"update MedicinalProductInteraction resource.\",\"responses\":{\"200\":{\"description\":\"successful operation\",\"content\":{\"application/fhir+json\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"}},\"examples\":{\"json-example\":{\"value\":{\"resourceType\":\"MedicinalProductInteraction\",\"id\":\"MedicinalProductInteraction-example\",\"description\":\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\",\"interactant\":[{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"ketoconazole\"}]}},{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"itraconazole\"}]}}],\"type\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionsType\",\"code\":\"StrongInhibitorofCYP3A4\"}]},\"effect\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionseffect\",\"code\":\"Increasedplasmaconcentrations\"}]},\"management\":{\"text\":\"Fa3DHffh0FEh4SC07X\"},\"meta\":{\"versionId\":\"20\",\"lastUpdated\":\"2022-02-17T23:28:26.332+08:00\"}}}}},\"application/fhir+xml\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"},\"xml\":{\"name\":\"MedicinalProductInteraction\"}},\"examples\":{\"xml-example\":{\"value\":\"\u003c?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?\u003e\u003cMedicinalProductInteraction xmlns=\\\"http://hl7.org/fhir\\\"\u003e\u003cid value=\\\"MedicinalProductInteraction-example\\\"/\u003e\u003cmeta\u003e\u003cversionId value=\\\"22\\\"/\u003e\u003clastUpdated value=\\\"2022-02-18T00:39:39.688+08:00\\\"/\u003e\u003c/meta\u003e\u003cdescription value=\\\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\\\"/\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"ketoconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"itraconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003ctype\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionsType\\\"/\u003e\u003ccode value=\\\"StrongInhibitorofCYP3A4\\\"/\u003e\u003c/coding\u003e\u003c/type\u003e\u003ceffect\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionseffect\\\"/\u003e\u003ccode value=\\\"Increasedplasmaconcentrations\\\"/\u003e\u003c/coding\u003e\u003c/effect\u003e\u003cmanagement\u003e\u003ctext value=\\\"Fa3DHffh0FEh4SC07X\\\"/\u003e\u003c/management\u003e\u003c/MedicinalProductInteraction\u003e\"}}}}},\"400\":{\"description\":\"error\",\"content\":{\"application/fhir+json\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"}},\"examples\":{\"Bad-Request-Response\":{\"value\":{\"resourceType\":\"OperationOutcome\",\"issue\":[{\"severity\":\"error\",\"code\":\"exception\",\"diagnostics\":\"validation error, path `resourceType` is required\"}]}}}},\"application/fhir+xml\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"},\"xml\":{\"name\":\"OperationOutcome\"}},\"examples\":{\"Bad-Request-Response\":{\"value\":\"\\n\u003cOperationOutcome xmlns='http://hl7.org/fhir'\u003e\\n\u003cissue\u003e\\n    \u003cseverity value='error'/\u003e\\n    \u003ccode value='exception'/\u003e\\n    \u003cdiagnostics value='validation error, path `resourceType` is required'/\u003e\\n\u003c/issue\u003e\\n\u003c/OperationOutcome\u003e\"}}}}}},\"x-codeSamples\":[{\"lang\":\"Shell\",\"source\":\"#example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\\ncurl --location --request PUT 'http://burni.example.com/fhir/MedicinalProductInteraction/MedicinalProductInteraction-example \\\\' \\n--header 'Content-Type: application/fhir+json' \\\\\\n--data-raw '{\\\"resourceType\\\":\\\"MedicinalProductInteraction\\\",\\\"id\\\":\\\"example\\\",\\\"text\\\":{\\\"status\\\":\\\"generated\\\",\\\"div\\\":\\\"\u003cdiv xmlns=\\\\\\\"http://www.w3.org/1999/xhtml\\\\\\\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative with Details\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: example\u003c/p\u003e\u003cp\u003e\u003cb\u003edescription\u003c/b\u003e: Inhibitors of CYP3A4 and P-gp\\\\\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\\\\\nequixaban Cmax.\\\\\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\\\\\nsection 4.4).\\\\\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: ketoconazole \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactant code 'ketoconazole' = 'ketoconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: itraconazole \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactant code 'itraconazole' = 'itraconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: StrongInhibitorofCYP3A4 \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactionsType code 'StrongInhibitorofCYP3A4' = 'StrongInhibitorofCYP3A4)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eeffect\u003c/b\u003e: Increasedplasmaconcentrations \u003cspan\u003e(Details : {http://ema.europa.eu/example/interactionseffect code 'Increasedplasmaconcentrations' = 'Increasedplasmaconcentrations)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003emanagement\u003c/b\u003e: Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp \u003cspan\u003e(Details )\u003c/span\u003e\u003c/p\u003e\u003c/div\u003e\\\"},\\\"description\\\":\\\"Inhibitors of CYP3A4 and P-gp\\\\\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\\\\\nequixaban Cmax.\\\\\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\\\\\nsection 4.4).\\\\\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\\\",\\\"interactant\\\":[{\\\"itemCodeableConcept\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactant\\\",\\\"code\\\":\\\"ketoconazole\\\"}]}},{\\\"itemCodeableConcept\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactant\\\",\\\"code\\\":\\\"itraconazole\\\"}]}}],\\\"type\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactionsType\\\",\\\"code\\\":\\\"StrongInhibitorofCYP3A4\\\"}]},\\\"effect\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactionseffect\\\",\\\"code\\\":\\\"Increasedplasmaconcentrations\\\"}]},\\\"management\\\":{\\\"text\\\":\\\"Fa3DHffh0FEh4SC07X\\\"},\\\"meta\\\":{\\\"tag\\\":[{\\\"system\\\":\\\"http://terminology.hl7.org/CodeSystem/v3-ActReason\\\",\\\"code\\\":\\\"HTEST\\\",\\\"display\\\":\\\"T03Ke3vZhQ\\\"}]}}'\",\"label\":\"cURL\"},{\"lang\":\"JavaScript\",\"source\":\" //example from: https://chinlinlee.github.io/Burni/assets/FHIR/fhir-resource-examples/medicinalproductinteraction-example.json\\nconst axios = require('axios');\\nconst data = {\\\"resourceType\\\":\\\"MedicinalProductInteraction\\\",\\\"id\\\":\\\"MedicinalProductInteraction-example\\\",\\\"description\\\":\\\"Inhibitors of CYP3A4 and P-gp\\\\\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\\\\\nequixaban Cmax.\\\\\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\\\\\nsection 4.4).\\\\\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\\\",\\\"interactant\\\":[{\\\"itemCodeableConcept\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactant\\\",\\\"code\\\":\\\"ketoconazole\\\"}]}},{\\\"itemCodeableConcept\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactant\\\",\\\"code\\\":\\\"itraconazole\\\"}]}}],\\\"type\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactionsType\\\",\\\"code\\\":\\\"StrongInhibitorofCYP3A4\\\"}]},\\\"effect\\\":{\\\"coding\\\":[{\\\"system\\\":\\\"http://ema.europa.eu/example/interactionseffect\\\",\\\"code\\\":\\\"Increasedplasmaconcentrations\\\"}]},\\\"management\\\":{\\\"text\\\":\\\"Fa3DHffh0FEh4SC07X\\\"},\\\"meta\\\":{\\\"versionId\\\":\\\"20\\\",\\\"lastUpdated\\\":\\\"2022-02-17T23:28:26.332+08:00\\\"}}\\nconst config = {\\n    method: 'put',\\n    url: 'http://burni.example.com/fhir/MedicinalProductInteraction/MedicinalProductInteraction-example',\\n    headers: { \\n        'Content-Type': 'application/fhir+json'\\n    },\\n    data: data\\n};\\n\\naxios(config)\\n.then(function (response) {\\n    console.log(JSON.stringify(response.data));\\n})\\n.catch(function (error) {\\n    console.log(error);\\n});\",\"label\":\"javascript Axios\"}]}},\"/fhir/MedicinalProductInteraction/\":{\"get\":{\"operationId\":\"search-typeMedicinalProductInteraction\",\"tags\":[\"MedicinalProductInteraction\"],\"summary\":\"search-type MedicinalProductInteraction resource by id.\",\"parameters\":[{\"name\":\"subject\",\"in\":\"query\",\"required\":false,\"schema\":{\"type\":\"string\"},\"description\":\"The medication for which this is an interaction\"}],\"responses\":{\"200\":{\"description\":\"successful operation\",\"content\":{\"application/fhir+json\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"}},\"examples\":{\"Success-Response\":{\"value\":{\"resourceType\":\"Bundle\",\"type\":\"searchset\",\"total\":1,\"link\":[{\"relation\":\"self\",\"url\":\"http://burni.example.com/fhir/MedicinalProductInteraction?_offset=0\u0026_count=100\"}],\"entry\":[{\"fullUrl\":\"http://burni.example.com/fhir/MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93\",\"resource\":{\"resourceType\":\"MedicinalProductInteraction\",\"id\":\"34868be2-3b67-4938-8c82-de12c8506b93\",\"description\":\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\",\"interactant\":[{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"ketoconazole\"}]}},{\"itemCodeableConcept\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactant\",\"code\":\"itraconazole\"}]}}],\"type\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionsType\",\"code\":\"StrongInhibitorofCYP3A4\"}]},\"effect\":{\"coding\":[{\"system\":\"http://ema.europa.eu/example/interactionseffect\",\"code\":\"Increasedplasmaconcentrations\"}]},\"management\":{\"text\":\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\"},\"meta\":{\"tag\":[{\"system\":\"http://terminology.hl7.org/CodeSystem/v3-ActReason\",\"code\":\"HTEST\",\"display\":\"test health data\"}],\"versionId\":\"1\",\"lastUpdated\":\"2022-02-13T22:30:17.988+08:00\"}}}]}},\"No-Match\":{\"value\":{\"resourceType\":\"Bundle\",\"type\":\"searchset\",\"total\":0,\"link\":[{\"relation\":\"self\",\"url\":\"http://localhost:8090/fhir/Patient?name=1\u0026_offset=0\u0026_count=100\"}]}}}},\"application/fhir+xml\":{\"schema\":{\"type\":\"object\",\"items\":{\"$ref\":\"#/components/schemas/FHIR-XML-RESOURCE\"},\"xml\":{\"name\":\"Bundle\"}},\"examples\":{\"Success-Response-XML\":{\"value\":\"\u003c?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?\u003e\\n\u003cBundle xmlns=\\\"http://hl7.org/fhir\\\"\u003e\\n    \u003ctype value=\\\"searchset\\\"/\u003e\\n    \u003ctotal value=\\\"1\\\"/\u003e\\n    \u003clink\u003e\\n        \u003crelation value=\\\"self\\\"/\u003e\\n        \u003curl value=\\\"http://burni.example.com/fhir/MedicinalProductInteraction?_offset=0\u0026amp;_count=100\\\"/\u003e\\n    \u003c/link\u003e\\n    \u003centry\u003e\\n        \u003cfullUrl value=\\\"http://burni.example.com/fhir/MedicinalProductInteraction/34868be2-3b67-4938-8c82-de12c8506b93\\\"/\u003e\\n        \u003cresource\u003e\\n            \u003c?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?\u003e\u003cMedicinalProductInteraction xmlns=\\\"http://hl7.org/fhir\\\"\u003e\u003cid value=\\\"936a22b3-5ea8-4f97-9105-300c41e8776b\\\"/\u003e\u003cmeta\u003e\u003cversionId value=\\\"1\\\"/\u003e\u003clastUpdated value=\\\"2022-02-17T17:34:54.876+08:00\\\"/\u003e\u003ctag\u003e\u003csystem value=\\\"http://terminology.hl7.org/CodeSystem/v3-ActReason\\\"/\u003e\u003ccode value=\\\"HTEST\\\"/\u003e\u003cdisplay value=\\\"test health data\\\"/\u003e\u003c/tag\u003e\u003c/meta\u003e\u003cdescription value=\\\"Inhibitors of CYP3A4 and P-gp\\\\nCoadministration of equixaban with ketoconazole (400 mg once a day), a strong inhibitor of both\\\\nCYP3A4 and P-gp, led to a 2-fold increase in mean equixaban AUC and a 1.6-fold increase in mean\\\\nequixaban Cmax.\\\\nThe use of Eliquis is not recommended in patients receiving concomitant systemic treatment with\\\\nstrong inhibitors of both CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole,\\\\nitraconazole, voriconazole and posaconazole) and HIV protease inhibitors (e.g., ritonavir) (see\\\\nsection 4.4).\\\\nActive substances which are not considered strong inhibitors of both CYP3A4 and P-gp,\\\\n(e.g., diltiazem, naproxen, amiodarone, verapamil, quinidine) are expected to increase equixaban\\\\nplasma concentration to a lesser extent. Diltiazem (360 mg once a day), for instance, considered a moderate CYP3A4 and a weak P-gp inhibitor, led to a 1.4-fold increase in mean equixaban AUC and a 1.3-fold increase in Cmax. Naproxen (500 mg, single dose) an inhibitor of P-gp but not an inhibitor of CYP3A4, led to a 1.5-fold and 1.6-fold increase in mean equixaban AUC and Cmax, respectively. No dose adjustment for equixaban is required when coadministered with less potent inhibitors of CYP3A4 and/or P-gp.\\\"/\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"ketoconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003cinteractant\u003e\u003citemCodeableConcept\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactant\\\"/\u003e\u003ccode value=\\\"itraconazole\\\"/\u003e\u003c/coding\u003e\u003c/itemCodeableConcept\u003e\u003c/interactant\u003e\u003ctype\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionsType\\\"/\u003e\u003ccode value=\\\"StrongInhibitorofCYP3A4\\\"/\u003e\u003c/coding\u003e\u003c/type\u003e\u003ceffect\u003e\u003ccoding\u003e\u003csystem value=\\\"http://ema.europa.eu/example/interactionseffect\\\"/\u003e\u003ccode value=\\\"Increasedplasmaconcentrations\\\"/\u003e\u003c/coding\u003e\u003c/effect\u003e\u003cmanagement\u003e\u003ctext value=\\\"Coadministration not recommended in patients receiving concomitant systemic treatment strong inhibitors of both CYP3A4 and P-gp\\\"/\u003e\u003c/management\u003e\u003c/MedicinalProductInteraction\u003e\\n        \u003c/resource\u003e\\n    \u003c/entry\u003e\\n\u003c/Bundle\u003e\"},\"No-Match\":{\"value\":\"\u003c?xml version=\\\"1.0\\\" encoding=\\\"UTF-8\\\"?\u003e\\n\u003cBundle xmlns=\\\"http://hl7.org/fhir\\\"\u003e\\n    \u003ctype value=\\\"searchset\\\"/\u003e\\n    \u003ctotal value=\\\"0\\\"/\u003e\\n    \u003clink\u003e\\n        \u003crelation value=\\\"self\\\"/\u003e\\n        \u003curl value=\\\"http://burni.example.com/fhir/MedicinalProductInteraction?_offset=0\u0026amp;_count=100\\\"/\u003e\\n    \u003c/link\u003e\\n\u003c/Bundle\u003e\"}}}}}},\"x-codeSamples\":[{\"lang\":\"Shell\",\"source\":\"curl --location --request GET 'http://burni.example.com/fhir/MedicinalProductInteraction'\",\"label\":\"cURL\"},{\"lang\":\"JavaScript\",\"source\":\"const axios = require('axios');\\nconst config = {\\n    method: 'get',\\n    url: 'http://burni.example.com/fhir/MedicinalProductInteraction'\\n};\\n\\naxios(config)\\n.then(function (response) {\\n    console.log(JSON.stringify(response.data));\\n})\\n.catch(function (error) {\\n    console.log(error);\\n});\",\"label\":\"javascript Axios\"}]}}},\"components\":{\"schemas\":{\"createMedicinalProductInteraction\":{\"properties\":{\"resourceType\":{\"type\":\"string\",\"description\":\"\"}},\"required\":[\"resourceType\"]},\"FHIR-JSON-RESOURCE\":{\"properties\":{}},\"FHIR-XML-RESOURCE\":{\"properties\":{}},\"deleteMedicinalProductInteraction\":{\"properties\":{\"id\":{\"type\":\"string\",\"description\":\"Resource ID in server\"}},\"required\":[\"id\"]},\"readMedicinalProductInteraction\":{\"properties\":{\"id\":{\"type\":\"string\",\"description\":\"Resource ID in server\"}},\"required\":[\"id\"]},\"updateMedicinalProductInteraction\":{\"properties\":{\"id\":{\"type\":\"string\",\"description\":\"Resource ID that you want to update\"},\"resourceType\":{\"type\":\"string\",\"description\":\"\"}},\"required\":[\"id\",\"resourceType\"]}}}}"
		}
	},
	"Error": "parse: parse spec: parse operations: paths: /fhir/MedicinalProductInteraction: post: operation \"createMedicinalProductInteraction\": responses: 400: content: \"application/fhir+json\": schema: parse schema: object cannot contain 'items' field"
}